Pharmacological targeting of neutrophils and their chemokine receptor CXCR2, or genetic ablation of the neutrophil recruiting chemokine Cxcl1, results in extended survival of PDGFB-driven tumor-bearing qMCP-deficient mice but not WT tumor-bearing mice. This evidence concerns the gene CXCL1 and neoplasm.